China NT Pharma Group Company Limited provided earnings guidance for the six months ending June 30, 2019. The Group is expected to record a profit for the Period Under Review but the profit may be substantially lower than that for the corresponding period in 2018. The reduced profitability is mainly due to the decrease in operating income as a result of the external policies faced by the Group and the continuing challenging business environment, as well as the increase in business development costs and operating expenses for the Period under Review. The Group endeavors to enhance the profitability for the whole year of 2019 by continually improving its business performance in the second half of the year.